CDP-choline reduces dopaminergic cell loss induced by MPP+ and glutamate in primary mesencephalic cell culture

International Journal of Neuroscience

Volumn 117, Issue 7, 2007, Pages 985-998

  Radad, Khaled ^a   Gille, Gabriele ^b   Xiaojing, Jia ^c   Durany, Nuria ^d   Rausch, Wolf Dieter ^e  

^a Assiut University   (Egypt)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^d UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^e UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Citicoline; Dopaminergic; Glutamate; MPP+; Neuroprotection; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CITICOLINE; GLUTAMIC ACID; PROPIDIUM IODIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL LOSS; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; EMBRYO; FEMALE; MESENCEPHALON; MOUSE; NEUROPROTECTION; NONHUMAN;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; CELL DEATH; CELLS, CULTURED; CYTIDINE DIPHOSPHATE CHOLINE; DOPAMINE; GLUTAMIC ACID; MESENCEPHALON; MICE; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; TYROSINE 3-MONOOXYGENASE;

EID: 34347399269     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.1080/10623320600934341     Document Type: Article

References (32)

1. Adibhatla, R. M., & Hatcher, J. F. (2005). Cytidine 5′-diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochemical Research, 30(1), 15-23.
2. Adibhatla, R. M., Hatcher, J. F., & Dempsey, R. J. (2001). Effects of citicoline on phospholipid and glutathione levels in transient cerebral ischemia. Stroke, 32(10), 2376-2381.
3. Adibhatla, R. M., Hatcher, J. F., & Dempsey, R. J. (2002). Citicoline: Neuroprotective mechanisms in cerebral ischemia. Journal of Neurochemistry, 80(1), 12-23.
4. Adibhatla, R. M., Hatcher, J. F., & Dempsey, R. J. (2003). Phospholipase A2, hydroxyl radicals, and lipid peroxidation in transient cerebral ischemia. Antioxidants & Redox Signaling, 5(5), 647-654.
5. Adibhatla, R. M., Hatcher, J. F., Larsen, E. C., Chen, X., Sun, D., & Tsao, F. H. (2006). CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP: Phosphocholine cytidylyltransferase after stroke. Journal of Biological Chemistry, 281(10), 6718-6725.
6. Agnoli, A., Ruggieri, S., Denaro, A., & Bruno, G. (1982). New strategies in the management of Parkinson's disease: A biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology, 8(6), 289-296.
7. Agut, J., Font, E., Sacristan, A., & Ortiz, J. A. (1983). Bioavailability of methyl-14 C CDP-choline by oral route. Arzneimittel- Forschung, 33(7A), 1045-1047.
8. Anderson, C. M., & Swanson, R. A. (2000). Astrocyte glutamate transport: Review of properties, regulation, and physiological functions. Glia, 32(1), 1-14.
9. Barrachina, M., Dominguez, I., Ambrosio, S., Secades, J., Lozano, R., & Ferrer, I. (2003). Neuroprotective effect of citicoline in 6-hydroxydopamine-lesioned rats and in 6-hydroxydopamine-treated SH-SY5Y human neuroblastoma cells. Journal of the Neurological Sciences, 215(1-2), 105-110.
10. Barrachina, M., Secades, J., Lozano, R., Gomez-Santos, C., Ambrosio, S., & Ferrer, I. (2002). Citicoline increases glutathione redox ratio and reduces caspase-3 activation and cell death in staurosporine-treated SH-SY5Y human neuroblastoma cells. Brain Research, 957(1), 84-90.
11. Baskaya, M. K., Dogan, A., Rao, A. M., & Dempsey, R. J. (2000). Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. Journal of Neurosurgery, 92(3), 448-452.
12. Brana, C., Benham, C., & Sundstrom, L. (2002). A method for characterising cell death in vitro by combining propidium iodide staining with immunohistochemistry. Brain Research Brain Research Protocols, 10(2), 109-114.
13. Conant, R., & Schauss, A. G. (2004). Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: A review of the literature. Alternative Medicine Review, 9(1), 17-31.
14. Crespo, D., Megias, M., Fernandez-Viadero, C., & Verduga, R. (2004). Chronic treatment with a precursor of cellular phosphatidylcholine ameliorates morphological and behavioral effects of aging in the mouse [correction of rat] hippocampus. Annals of the New York Academy of Sciences, 1019, 41-43.
15. Eberhardt, R., Birbamer, G., Gerstenbrand, F., Rainer, E., & Traegner, H. (1990). Citicoline in the treatment of Parkinson's disease. Clinical Therapeutics, 12(6), 489-495.
16. Galletti, P., De Rosa, M., Cotticelli, M. G., Morana, A., Vaccaro, R., & Zappia, V. (1991). Biochemical rationale for the use of CDPcholine in traumatic brain injury: pharmacokinetics of the orally administered drug. Journal of the Neurological Sciences, 103(Suppl), S19-S25.
17. Gille, G., Radad, K., Reichmann, H., & Rausch, W. D. (2006). Synergistic effect of alpha-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture. Journal of Neural Transmission, 113(10), 1383-1393.
18. Grieb, P., Gadamski, R., Wojda, R., & Janisz, M. (2001). CDP-choline, but not cytidine, protects hippocampal CA1 neurones in the gerbil following transient forebrain ischaemia. Folia Neuropathologica, 39(3), 141-145.
19. Grieb, P., & Rejdak, R. (2002). Pharmacodynamics of citicoline relevant to the treatment of glaucoma. Journal of Neuroscience Research, 67(2), 143-148.
20. Hurtado, O., Moro, M. A., Cardenas, A., Sanchez, V., Fernandez-Tome, P., Leza, J. C., Lorenzo, P., Secades, J. J., Lozano, R., Davalos, A., Castillo, J., & Lizasoain, I. (2005). Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiology of Disease, 18(2), 336-345.
21. Kent, C., & Carman, G. M. (1999). Interactions among pathways for phosphatidylcholine metabolism, CTP synthesis and secretion through the Golgi apparatus. Trends in Biochemical Sciences, 24(4), 146-150.
22. Krupinski, J., Ferrer, I., Barrachina, M., Secades, J. J., Mercadal, J., & Lozano, R. (2002). CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear DNA fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. Neuropharmacology, 42(6), 846-854.
23. Krupinski, J., Slevin, M., & Badimon, L. (2005). Citicoline inhibits MAP kinase signalling pathways after focal cerebral ischaemia. Neurochemical Research, 30(8), 1067-1073.
24. Lipton, S. A., & Rosenberg, P. A. (1994). Excitatory amino acids as a final common pathway for neurologic disorders. New England Journal of Medicine, 330(9), 613-622.
25. Lopez, G. -C., Agut, J., Ortiz, J. A., & Wurtman, R. J. (1992). Effects of orally administered cytidine 5′-diphosphate choline on brain phospholipid content. Journal of Nutritional Biochemistry, 3(6), 313-315.
26. McDaniel, M. A., Maier, S. F., & Einstein, G. O. (2003). "Brain-specific" nutrients: A memory cure Nutrition, 19, 957-975.
27. Meldrum, B. S. (1998). The glutamate synapse as a therapeutical target: Perspectives for the future. Progress in Brain Research, 116, 441-458.
28. Mir, C., Clotet, J., Aledo, R., Durany, N., Argemi, J., Lozano, R., Cervos-Navarro, J., & Casals, N. (2003). CDP-choline prevents glutamate-mediated cell death in cerebellar granule neurons. Journal of Molecular Neuroscience, 20(1), 53-60.
29. Savci, V., & Wurtman, R. J. (1995). Effect of cytidine on membrane phospholipid synthesis in rat striatal slices. Journal of Neurochemistry, 64(1), 378-384.
30. Secades, J. J., & Frontera, G. (2002). CDP-choline: Update and review of its pharmacology and clinical use. Methods and Findings in Experimental and Clinical Pharmacology, 24, 1-53.
31. Teather, L. A., & Wurtman, R. J. (2005). Dietary CDP-choline supplementation prevents memory impairment caused by impoverished environmental conditions in rats. Learning and Memory, 12(1), 39-43.
32. Weiss, G. B. (1995). Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sciences, 56(9), 637-660.